Drugs · acquisition-cost intelligence
Cyclosporine
· ingredient cyclosporineOther ophthalmologicals· CYCLOSPORINE 100 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$2.35
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other cyclosporine products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| CycloSPORINE, Modfied | $0.71770 | −$1.63 |
| RESTASIS | $1.52 | −$0.83100 |
| Cyclosporine | $5.58 | +$3.23 |
| Restasis MultiDose | $112.33 | +$109.98 |
| VEVYE | $368.89 | +$366.55 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 4
Prior auth 100% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.